Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) Shares Repurchased (2010)

Harvard Bioscience (HBIO) reported Shares Repurchased of $10.0 million for Q4 2010, up 407.79% on a QoQ basis from -$3.2 million in Q3 2010.

Harvard Bioscience (HBIO) has 1 years of Shares Repurchased data on file, last reported at $10.0 million in Q4 2010.

  • Quarterly Shares Repurchased changed N/A year-over-year to $10.0 million in Q4 2010, while the trailing twelve-month figure through Dec 2011 was $6.8 million (changed N/A YoY) and the FY2010 annual result came in at $5.0 million, up 107.99% from the prior year.
  • Shares Repurchased rose to $10.0 million in Q4 2010 per HBIO's latest filing, from -$3.2 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $10.0 million in Q4 2010 and bottomed at -$3.2 million in Q3 2010.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn 1.12 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn 2.00 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 175.01 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn 297.60 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn 67.00 Mn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 92.50 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 31.20 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn -
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 99.97 Mn
10 Harvard Bioscience 25.38 Mn 18.29 Mn 12.24 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2010 10.00 Mn
Dec 31, 2010 10.00 Mn
Sep 30, 2010 -3.25 Mn
Sep 30, 2010 -3.25 Mn